{"url_path":"/sec/pyxs/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-294613-index.html","accession_number":"0001193125-26-294613","cik":"0001782223","ticker":"PYXS","issuer_name":"Pyxis Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-294613-index.html","primary_entity_key":"0001782223","primary_entity_name":"Pyxis Oncology, Inc."},"word_count":142,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\n(d) Exhibits\n\n \n\nExhibit No.\n\nDescription\n\n4.1\n\n[Form of Common Warrant](pyxs-ex4_1.htm)\n\n10.1*\n\n[Securities Purchase Agreement, dated June 30, 2026, by and among Pyxis Oncology, Inc. and each of the purchasers as party thereto](pyxs-ex10_1.htm)\n\n10.2\n\n[Form of Registration Rights Agreement](pyxs-ex10_2.htm)\n\n99.1\n\n[Press Release dated June 30, 2026](pyxs-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nPyxis Oncology, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJuly 2, 2026\n\nBy:\n\n/s/ Jitendra Wadhane\n\n \n\n \n\n \n\nJitendra Wadhane\nPrincipal Financial and Accounting Officer"}